Tumor Necrosis Factor Ligand Superfamily Member 11 (Receptor Activator Of Nuclear Factor Kappa B Ligand or Osteoclast Differentiation Factor or TNF Related Activation Induced Cytokine or Osteoprotegerin Ligand or CD254 or TNFSF11) - Pipeline Review, H2 2016

Published: Aug, 2016 | Pages: 70 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Tumor Necrosis Factor Ligand Superfamily Member 11 (Receptor Activator Of Nuclear Factor Kappa B Ligand or Osteoclast Differentiation Factor or TNF Related Activation Induced Cytokine or Osteoprotegerin Ligand or CD254 or TNFSF11) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Tumor Necrosis Factor Ligand Superfamily Member 11 (Receptor Activator Of Nuclear Factor Kappa B Ligand or Osteoclast Differentiation Factor or TNF Related Activation Induced Cytokine or Osteoprotegerin Ligand or CD254 or TNFSF11) - Pipeline Review, H2 2016', provides in depth analysis on Tumor Necrosis Factor Ligand Superfamily Member 11 (Receptor Activator Of Nuclear Factor Kappa B Ligand or Osteoclast Differentiation Factor or TNF Related Activation Induced Cytokine or Osteoprotegerin Ligand or CD254 or TNFSF11) targeted pipeline therapeutics. 

The report provides comprehensive information on the Tumor Necrosis Factor Ligand Superfamily Member 11 (Receptor Activator Of Nuclear Factor Kappa B Ligand or Osteoclast Differentiation Factor or TNF Related Activation Induced Cytokine or Osteoprotegerin Ligand or CD254 or TNFSF11), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Tumor Necrosis Factor Ligand Superfamily Member 11 (Receptor Activator Of Nuclear Factor Kappa B Ligand or Osteoclast Differentiation Factor or TNF Related Activation Induced Cytokine or Osteoprotegerin Ligand or CD254 or TNFSF11) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Tumor Necrosis Factor Ligand Superfamily Member 11 (Receptor Activator Of Nuclear Factor Kappa B Ligand or Osteoclast Differentiation Factor or TNF Related Activation Induced Cytokine or Osteoprotegerin Ligand or CD254 or TNFSF11)
- The report reviews Tumor Necrosis Factor Ligand Superfamily Member 11 (Receptor Activator Of Nuclear Factor Kappa B Ligand or Osteoclast Differentiation Factor or TNF Related Activation Induced Cytokine or Osteoprotegerin Ligand or CD254 or TNFSF11) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Tumor Necrosis Factor Ligand Superfamily Member 11 (Receptor Activator Of Nuclear Factor Kappa B Ligand or Osteoclast Differentiation Factor or TNF Related Activation Induced Cytokine or Osteoprotegerin Ligand or CD254 or TNFSF11) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Tumor Necrosis Factor Ligand Superfamily Member 11 (Receptor Activator Of Nuclear Factor Kappa B Ligand or Osteoclast Differentiation Factor or TNF Related Activation Induced Cytokine or Osteoprotegerin Ligand or CD254 or TNFSF11) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Tumor Necrosis Factor Ligand Superfamily Member 11 (Receptor Activator Of Nuclear Factor Kappa B Ligand or Osteoclast Differentiation Factor or TNF Related Activation Induced Cytokine or Osteoprotegerin Ligand or CD254 or TNFSF11) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Tumor Necrosis Factor Ligand Superfamily Member 11 (Receptor Activator Of Nuclear Factor Kappa B Ligand or Osteoclast Differentiation Factor or TNF Related Activation Induced Cytokine or Osteoprotegerin Ligand or CD254 or TNFSF11)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Tumor Necrosis Factor Ligand Superfamily Member 11 (Receptor Activator Of Nuclear Factor Kappa B Ligand or Osteoclast Differentiation Factor or TNF Related Activation Induced Cytokine or Osteoprotegerin Ligand or CD254 or TNFSF11) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Tumor Necrosis Factor Ligand Superfamily Member 11 (Receptor Activator Of Nuclear Factor Kappa B Ligand or Osteoclast Differentiation Factor or TNF Related Activation Induced Cytokine or Osteoprotegerin Ligand or CD254 or TNFSF11) Overview 8
Therapeutics Development 9
Tumor Necrosis Factor Ligand Superfamily Member 11 (Receptor Activator Of Nuclear Factor Kappa B Ligand or Osteoclast Differentiation Factor or TNF Related Activation Induced Cytokine or Osteoprotegerin Ligand or CD254 or TNFSF11) - Products under Development by Stage of Development 9
Tumor Necrosis Factor Ligand Superfamily Member 11 (Receptor Activator Of Nuclear Factor Kappa B Ligand or Osteoclast Differentiation Factor or TNF Related Activation Induced Cytokine or Osteoprotegerin Ligand or CD254 or TNFSF11) - Products under Development by Therapy Area 10
Tumor Necrosis Factor Ligand Superfamily Member 11 (Receptor Activator Of Nuclear Factor Kappa B Ligand or Osteoclast Differentiation Factor or TNF Related Activation Induced Cytokine or Osteoprotegerin Ligand or CD254 or TNFSF11) - Products under Development by Indication 11
Tumor Necrosis Factor Ligand Superfamily Member 11 (Receptor Activator Of Nuclear Factor Kappa B Ligand or Osteoclast Differentiation Factor or TNF Related Activation Induced Cytokine or Osteoprotegerin Ligand or CD254 or TNFSF11) - Pipeline Products Glance 12
Late Stage Products 12
Early Stage Products 13
Tumor Necrosis Factor Ligand Superfamily Member 11 (Receptor Activator Of Nuclear Factor Kappa B Ligand or Osteoclast Differentiation Factor or TNF Related Activation Induced Cytokine or Osteoprotegerin Ligand or CD254 or TNFSF11) - Products under Development by Companies 14
Tumor Necrosis Factor Ligand Superfamily Member 11 (Receptor Activator Of Nuclear Factor Kappa B Ligand or Osteoclast Differentiation Factor or TNF Related Activation Induced Cytokine or Osteoprotegerin Ligand or CD254 or TNFSF11) - Products under Development by Universities/Institutes 16
Tumor Necrosis Factor Ligand Superfamily Member 11 (Receptor Activator Of Nuclear Factor Kappa B Ligand or Osteoclast Differentiation Factor or TNF Related Activation Induced Cytokine or Osteoprotegerin Ligand or CD254 or TNFSF11) - Therapeutics Assessment 18
Assessment by Monotherapy/Combination Products 18
Assessment by Mechanism of Action 19
Assessment by Route of Administration 20
Assessment by Molecule Type 22
Tumor Necrosis Factor Ligand Superfamily Member 11 (Receptor Activator Of Nuclear Factor Kappa B Ligand or Osteoclast Differentiation Factor or TNF Related Activation Induced Cytokine or Osteoprotegerin Ligand or CD254 or TNFSF11) - Companies Involved in Therapeutics Development 24
Ablynx NV 24
AlphaMab Co., Ltd 25
Amgen Inc. 26
Astellas Pharma Inc. 27
Clonz Biotech Private Limited 28
Intas Pharmaceuticals Ltd. 29
Oncobiologics, Inc. 30
R-Pharm 31
Tumor Necrosis Factor Ligand Superfamily Member 11 (Receptor Activator Of Nuclear Factor Kappa B Ligand or Osteoclast Differentiation Factor or TNF Related Activation Induced Cytokine or Osteoprotegerin Ligand or CD254 or TNFSF11) - Drug Profiles 32
ALX-0141 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
AMG-161 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
CDRI-99/373 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
denosumab - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
denosumab biosimilar - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
denosumab biosimilar - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
denosumab biosimilar - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
denosumab biosimilar - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
KN-012 - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
Monoclonal Antibody to Inhibit RANKL for Bone Disorders - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
Proteins to Inhibit RANKL for Oncology and Osteoporosis - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
RPH-203 - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
Small Molecules to Inhibit RANKL for Osteoclastogenesis - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
Tumor Necrosis Factor Ligand Superfamily Member 11 (Receptor Activator Of Nuclear Factor Kappa B Ligand or Osteoclast Differentiation Factor or TNF Related Activation Induced Cytokine or Osteoprotegerin Ligand or CD254 or TNFSF11) - Dormant Projects 54
Tumor Necrosis Factor Ligand Superfamily Member 11 (Receptor Activator Of Nuclear Factor Kappa B Ligand or Osteoclast Differentiation Factor or TNF Related Activation Induced Cytokine or Osteoprotegerin Ligand or CD254 or TNFSF11) - Featured News & Press Releases 55
Mar 30, 2016: Daiichi Sankyo Announces Phase 3 Clinical Trial Results for AMG 162 (denosumab) Rheumatoid Arthritis Treatment 55
Oct 12, 2015: New Data Show Consistent Safety Profile For Up To 10 Years With Prolia In Postmenopausal Women With Osteoporosis 55
Oct 11, 2015: New Data Show Greater Bone Mineral Density Gains With Prolia Compared With Zoledronic Acid 56
Oct 06, 2015: Amgen To Present Data From Multiple Studies For Prolia On Osteoporosis Disease And Treatment At American Society For Bone And Mineral Research Annual Meeting 57
Jul 06, 2015: R-Pharm Group of Companies Develops Original drug for Treatment of Metastatic Bone Disease 59
Jun 01, 2015: Amgen Presents Phase 3 Data At ASCO Showing Prolia (Denosumab) Significantly Reduced Bone Fractures In Breast Cancer Patients Receiving Aromatase Inhibitors 60
May 13, 2015: Amgen Presents Data At ASCO 2015 On Prolia 61
Sep 15, 2014: Amgen Announces Results From Several New Exploratory Analyses Evaluating Long-Term Impact Of Treatment With Prolia (Denosumab) In Postmenopausal Women With Osteoporosis 61
Sep 10, 2014: Amgen Announces 18 Abstracts To Be Presented At The American Society for Bone and Mineral Research 2014 Annual Meeting 63
Oct 04, 2013: Amgen Presents Data From Several Prolia Studies At ASBMR 64
Jun 11, 2013: Daiichi Sankyo Launches Pralia Subcutaneous Injection 60mg Syringe For Treatment Of Osteoporosis 65
Mar 25, 2013: Daiichi Sankyo Receives Japanese Approval For Manufacture And Marketing Of Pralia For Treatment Of Osteoporosis 66
Nov 21, 2012: Amgen Canada Provides New Safety Information For Prolia 66
Oct 15, 2012: Daiichi Sankyo Announces Positive Phase III Study Results For Denosumab On Fracture Risk In Japanese Patients With Osteoporosis At ASBMR 67
Oct 14, 2012: Amgen Presents Several Sub-Analysis From Pivotal Phase III Prolia Fracture Trial At ASBMR 2012 67
Appendix 69
Methodology 69
Coverage 69
Secondary Research 69
Primary Research 69
Expert Panel Validation 69
Contact Us 69
Disclaimer 70

List of Tables

Number of Products under Development for, H2 2016 9
Number of Products under Development by Therapy Area, H2 2016 10
Number of Products under Development by Indication, H2 2016 11
Comparative Analysis by Late Stage Development, H2 2016 12
Comparative Analysis by Early Stage Products, H2 2016 13
Number of Products under Development by Companies, H2 2016 14
Products under Development by Companies, H2 2016 15
Number of Products under Investigation by Universities/Institutes, H2 2016 16
Products under Investigation by Universities/Institutes, H2 2016 17
Assessment by Monotherapy/Combination Products, H2 2016 18
Number of Products by Stage and Mechanism of Action, H2 2016 19
Number of Products by Stage and Route of Administration, H2 2016 21
Number of Products by Stage and Molecule Type, H2 2016 23
Pipeline by Ablynx NV, H2 2016 24
Pipeline by AlphaMab Co., Ltd, H2 2016 25
Pipeline by Amgen Inc., H2 2016 26
Pipeline by Astellas Pharma Inc., H2 2016 27
Pipeline by Clonz Biotech Private Limited, H2 2016 28
Pipeline by Intas Pharmaceuticals Ltd., H2 2016 29
Pipeline by Oncobiologics, Inc., H2 2016 30
Pipeline by R-Pharm, H2 2016 31
Dormant Projects, H2 2016 54